Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Cash & Equivalents: 2020-2022

Historic Cash & Equivalents for Candel Therapeutics (CADL) over the last 3 years, with Dec 2022 value amounting to $70.1 million.

  • Candel Therapeutics' Cash & Equivalents fell 44.29% to $43.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $43.0 million, marking a year-over-year decrease of 44.29%. This contributed to the annual value of $70.1 million for FY2022, which is 15.23% down from last year.
  • According to the latest figures from FY2022, Candel Therapeutics' Cash & Equivalents is $70.1 million, which was down 15.23% from $82.6 million recorded in FY2021.
  • Candel Therapeutics' 5-year Cash & Equivalents high stood at $82.6 million for FY2021, and its period low was $35.1 million during FY2020.
  • Over the past 3 years, Candel Therapeutics' median Cash & Equivalents value was $70.1 million (recorded in 2022), while the average stood at $62.6 million.
  • As far as peak fluctuations go, Candel Therapeutics' Cash & Equivalents surged by 135.76% in 2021, and later declined by 15.23% in 2022.
  • Candel Therapeutics' Cash & Equivalents (Yearly) stood at $35.1 million in 2020, then skyrocketed by 135.76% to $82.6 million in 2021, then decreased by 15.23% to $70.1 million in 2022.